Miromatrix Medical Inc. (NASDAQ: MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and improve patients' lives, today announced that CEO Jeff Ross will present at the 2023 Cell & Gene Meeting on the Mesa in Carlsbad, CA. The three-day event, held this year on October 10-12, will feature presentations by leading public and private companies, highlighting technical and clinical achievements over the past 12 months in the areas of cell therapy, gene therapy, gene editing, tissue engineering, and broader regenerative medicine technologies.

Mr. Ross will deliver his remarks at 5:30 pm PT on Wednesday, October 11th in the Ecolab Lifesciences Ballroom. Registration for either in-person attendance or virtual participation is available here.

About MiromatrixMiromatrix Medical Inc. is a life sciences company pioneering a novel technology for bioengineering fully transplantable human organs to help save and improve patients' lives. The Company has developed a proprietary perfusion technology platform for bioengineering organs that it believes will efficiently scale to address the shortage of available human organs. The Company's initial development focus is on human livers and kidneys. For more information, visit miromatrix.com.

Investor Contact
Greg Chodaczek
347-620-7010
ir@miromatrix.com

Media Contact:
Christina Campbell
612-924-3793
Christina@media-minefield.com
Grafico Azioni MiroMatrix Medical (NASDAQ:MIRO)
Storico
Da Apr 2024 a Mag 2024 Clicca qui per i Grafici di MiroMatrix Medical
Grafico Azioni MiroMatrix Medical (NASDAQ:MIRO)
Storico
Da Mag 2023 a Mag 2024 Clicca qui per i Grafici di MiroMatrix Medical